Neuronetics Gives New Hope To People Suffering From Depression

Fans of “The Sound of Music” will remember the scene in which Liesl, the eldest Von Trapp daughter, radiantly sings “I am 16, going on 17.” But in real life, actress Charmian Carr, who played the teenager in the 1965 movie, hasn’t felt radiant for the past two decades. Now a grandmother, Carr has long suffered from severe clinical depression. Medications not only failed to help but also produced debilitating side effects. “People thought I had Parkinson’s disease because I shake so much from all of the medicines,” the actress explains in a June YouTube video made about her case by the UCLA Depression Research & Clinic Program.

Despite major advances in treating depression, nearly 30 percent of patients don’t benefit from drug therapy and more than half report side-effects that lead to non-compliance with medication regimes, such as tremors, sexual dysfunction, weight gain, and sleep disorders. But Carr and a growing number of patients who fail to improve with antidepressant drugs are now finding relief from a electromagnetic therapy called Transcranial Magnetic Stimulation (TMS.)

The therapy uses magnetic pulses to stimulate nerve cells in an area of the brain linked to depression. The stimulation increases brain activity and releases neurotransmitters, which are known to elevate mood. Although TMS has been studied for 25 years as a means of treating depression, Malvern, Penn.-based Neuronetics was the first to build a clinical system with reproducible results–and the first to receive U.S. Food and Drug Administration approval for the technology. Neurotetics is one of 31 companies named Sept. 1 by the Geneva-based World Economic Forum as Tech Pioneers offering new technologies or business models that could have a positive impact on peoples’ lives.

Neuronetics licensed a family of patents from Emory University in 2003 and completed the largest clinical trial ever performed using TMS. Today its TMS Therapy system is being used in 200 hospitals and doctors’ offices throughout the U.S., including in seven of the country’s top 10 psychiatric hospitals.

TMS is a 40-minute outpatient procedure performed under the supervision of a psychiatrist. No anesthesia or sedation is required. Patients sit in what looks like a reclined dental chair and place their heads on a headrest. The psychiatrist then places a treatment coil on the patient’s head. The coil emits magnetic field pulses aimed at the left prefrontal cortex, an area of the brain that has been demonstrated to function abnormally in patients with depression. The magnetic fields are the same type and strength as those used in magnetic resonance imaging (MRI) machines. Once inside the brain, these pulses activate regional neurons and their corresponding circuits. Such activation is thought to correspond with release of neurotransmitters such as serotonin, norepinepherine, and dopamine.

A typical course of outpatient TMS therapy involves 20 to 30 of these sessions, five days per week, over a four to six week period.

The cost varies between $300 to $600 per session depending on who administers the treatment and where it takes place. Some U.S. insurance companies, employers, and universities are starting to cover the care, says Dr. Linda Carpenter, chief of the mood disorders program at Butler Psychiatric Hospital in Providence, R.I., which has been using Neuronetics’ device to treat patients since January, 2009. The medical insurance offered to students at Brown University, for example, now covers TMS therapy for those in need of treatment for depression, says Carpenter, who also serves as an associate professor in Brown’s Psychiatry and Human Behavior Department.

Some 78 percent of patients at the Butler Hospital clinic reported feeling significantly better after TMS therapy, she says. A recently published study by the U.S. National Institute of Mental Health involving four U.S. university hospital clinics using Neuronetics’ system also gave high marks to TMS therapy. The study, conducted on 190 patients not being treated with antidepressant drugs, concluded that daily left prefrontal TMS therapy safely and effectively treats major depression disorder.

In a Neuronetics clinical trial, about one-third of people showed some slippage after six months, but 84 percent of those patients said their depression went into “remission” after booster TMS treatments.

In the June video made by UCLA’s Depression Clinic, actress Carr says that thanks to the TMS therapy she received there, she is able to function without antidepressants for the first time in more than 20 years and is even taking up dancing again. “To have another alternative has been wonderful, not only me, but for my family and my grandchildren,” she says. 

For a look at all this year’s winners, see a slideshow prepared by Informilo’s Jennifer L. Schenker which is running on and an in-depth report on each of the tech pioneers that Schenker prepared for the World Economic Forum.



Related posts

Comments are closed.